Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Biomark Med. 2009 Oct 1;3(5):513–523. doi: 10.2217/bmm.09.60

Figure 3. Circulating levels of TIMP-1 were compared between healthy controls and heart failure patients with NYHA classifications I, II, III and IV.

Figure 3

The log TIMP-1 levels, adjusted for age and gender, significantly increased with increasing NYHA classification. Both systolic and diastolic heart failure patients were included in this study. Controls: n = 74; NYHA I, II, III and IV: n = 35, 94, 98 and 22, respectively; p < 0.001.

NYHA: New York Heart Association; TIMP: Tissue inhibitor of matrix metalloproteinase.

Adapted from [28].